Table 1

Phase 3 trials evaluating alternative regimens to R-CHOP or evaluating high-dose therapy approaches

StudyPatientsRegimensOutcomeP value
Recher et al69  380 R-ACVBP 3-year PFS 87% vs 73% .002 
vs R-CHOP 3-year OS 92% vs 84% .007 
Cunningham et al71  1080 R-CHOP-14 2-year PFS 75% vs 75% NS 
vs R-CHOP 2-year OS 83% vs 81% NS 
Delarue et al72  602 R-CHOP-14 3-year EFS 56% vs 60% NS 
vs R-CHOP 3-year OS 69% vs 72% NS 
Le Gouill et al78  340 R-HDT + ASCT 3-year PFS 76%* NS 
vs R-CHOP-14 3-year OS 83% NS 
Schmitz et al79  275 R-Mega-CHOEP 3-year EFS 61% vs 70% NS 
vs R-CHOEP-14 3-year OS 77% vs 85% .08 
Vitolo et al80  399 R-HDT + ASCT 3-year PFS 70% vs 59% .01 
vs R-dose dense CT 3-year OS 81% vs 78% NS 
Stiff et al81  253 (R)-CHOP × 6 + ASCT 2-year PFS 69% vs 55% .005 
vs (R)-CHOP × 8† 2-year OS 74% vs 71% NS 
StudyPatientsRegimensOutcomeP value
Recher et al69  380 R-ACVBP 3-year PFS 87% vs 73% .002 
vs R-CHOP 3-year OS 92% vs 84% .007 
Cunningham et al71  1080 R-CHOP-14 2-year PFS 75% vs 75% NS 
vs R-CHOP 2-year OS 83% vs 81% NS 
Delarue et al72  602 R-CHOP-14 3-year EFS 56% vs 60% NS 
vs R-CHOP 3-year OS 69% vs 72% NS 
Le Gouill et al78  340 R-HDT + ASCT 3-year PFS 76%* NS 
vs R-CHOP-14 3-year OS 83% NS 
Schmitz et al79  275 R-Mega-CHOEP 3-year EFS 61% vs 70% NS 
vs R-CHOEP-14 3-year OS 77% vs 85% .08 
Vitolo et al80  399 R-HDT + ASCT 3-year PFS 70% vs 59% .01 
vs R-dose dense CT 3-year OS 81% vs 78% NS 
Stiff et al81  253 (R)-CHOP × 6 + ASCT 2-year PFS 69% vs 55% .005 
vs (R)-CHOP × 8† 2-year OS 74% vs 71% NS 

NS, not significant; R-HDT, rituximab with a high-dose therapy regimen; R-dose dense CT, rituximab with a dose dense chemotherapy regimen.

*

Results not reported separately per arm.

†

Only 47% of patients received rituximab.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal